Even though therapeutic options based on TLRs other than TLR4 have reached the stage of clinical trials for OC [105], there are still not enough to draw firm conclusions, since the expression of TLRs on immune cells and cancer cells seem to exert opposite effects. The gene discussed is TLR4; the disease is cancer.